On October 19, 2023 Foundation Medicine, Inc., reported that the company will present 11 abstracts demonstrating the value of high-quality biomarker tests to inform cancer care at the 2023 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Meeting from October 20-24 in Madrid, Spain (Press release, Foundation Medicine, OCT 19, 2023, View Source [SID1234636164]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Late Breaking Results from the CUPISCO Study
In a late-breaking abstract, Foundation Medicine and Roche share results from the randomized precision oncology study, CUPISCO, designed to prospectively assess the efficacy of molecularly guided therapy for patients with unfavorable subset cancer of unknown primary (CUP). In patients with CUP, the tumor of origin is unknown, which has historically made targeted treatment challenging. As a result, there has been little progress in improving the poor outcomes for these patients. The study demonstrates how genomic profiling using Foundation Medicine’s FDA-approved FoundationOneCDx and FoundationOneLiquid CDx diagnostic tests positively impacted progression-free survival and overall survival in patients with CUP.
Primary analysis of efficacy and safety in CUPISCO: A randomised, global study of targeted therapy or cancer immunotherapy guided by genomic profiling vs platinum-based chemotherapy (CTX) in patients (pts) with treatment-naive, unfavourable carcinoma-of-unknown-primary-origin (CUP) (Proffered Paper Session 1, LBA16)
Highlighting Expanded Capabilities of ctDNA Tumor Fraction
Research continues to validate the power of circulating tumor DNA (ctDNA) tumor fraction, which is a measurement of the level of ctDNA within a liquid biopsy sample, to support the interpretation of liquid biopsy test results. Two new studies being presented by Foundation Medicine and its collaborators at ESMO (Free ESMO Whitepaper) highlight the differentiated ctDNA tumor fraction reporting capabilities of the company’s FoundationOneLiquid CDx test. The research explores ctDNA tumor fraction’s correlation with metabolic tumor volume on with a PET scan, and its prognostic use in bladder cancer, respectively.
Clinical and genomic correlates of plasma circulating tumor DNA (ctDNA) tumor fraction (TF) in patients with advanced NSCLC (Presentation Number 2339P)
Relationship of Tumor Fraction in Circulating Tumor DNA (ctDNA) with Prognosis in Patients with Advanced Urothelial Cancer (Presentation Number 2396P)
Demonstrating Differences in Genetic Ancestry in Biliary Tract Cancer
Molecular differences between genetic ancestries in patients with biliary tract cancer (BTC) and the impact of those differences on prognosis and treatment response are largely unknown. In a study conducted with The University of Texas MD Anderson Cancer Center, researchers looked at over 10,000 cases of BTC in patients of African and European descent and identified key clinical and genomic differences.
Molecular Profiling of Biliary Tract Cancer (BTCs) in Patients of African and European ancestries (Presentation Number 113P)
"The research we are presenting at this year’s ESMO (Free ESMO Whitepaper) reinforces the ever-expanding clinical utility across disease types of our high-quality tissue and blood-based tests," says Mia Levy, MD, PhD, chief medical officer at Foundation Medicine. "Alongside our collaborators, we’re proud to share our continued progress in bringing more knowledge and cancer treatment options to the cancer community."
The following is a list of abstracts that will be presented at the meeting. To access all abstracts being presented at ESMO (Free ESMO Whitepaper), please visit ESMO (Free ESMO Whitepaper).org.
Follow Foundation Medicine on Twitter and LinkedIn for more updates from #ESMO23 and visit us in person at Booths 727 and 728.
Abstract #
Title
Collaborators
Product
Proffered Paper (Oral)
LBA16
Saturday, October 21
10:35-10:45 a.m.
Primary analysis of efficacy and safety in CUPISCO: A randomised, global study of targeted therapy or cancer immunotherapy guided by genomic profiling vs platinum-based chemotherapy (CTX) in patients (pts) with treatment-naive, unfavourable carcinoma-of-unknown-primary-origin (CUP)
Oncologists from Europe, Asia and Oceania, Central lab at University Hospital of Zurich
FoundationOneCDx
FoundationOneLiquid CDx
1182O
Sunday, October 22
9:20-9:30 a.m.
Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well differentiated pancreatic neuroendocrine tumors
Hôpital Saint-Louis AP-HP
FoundationOneCDx
Posters
2352P
Sunday, October 22
Sex-Based Difference in Gene Alterations and Biomarkers in Anal Squamous Cell Carcinoma
IRCCS San Raffaele Scientific Institute
FoundationOneCDx
771P
Sunday, October 22
Genomic Characterization of Advanced Endometrial Carcinosarcoma: Identification of Potentially Actionable Targets
IRCCS Istituto Romagnolo per lo Studio dei Tumori, IRCCS San Raffaele Scientific Institute, IRCCS Istituto Nazionale Tumori
FoundationOneCDx
2339P
Sunday, October 22
Clinical and genomic correlates of plasma circulating tumor DNA (ctDNA) tumor fraction (TF) in patients with advanced NSCLC
Institut Gustave Roussy
FoundationOneLiquid CDx
113P
Monday, October 23
Molecular Profiling of Biliary Tract Cancer (BTCs) in Patients of African and European ancestries
MD Anderson
FoundationOneCDx
738P
Monday, October 23
Penile squamous cell carcinoma with high and very high tumor mutational burden: A genomic landscape and real-world clinical outcome study
Upstate Medical University, University of Washington, Moffit Cancer Center,
MD Anderson Cancer Center, San Rafael University
FoundationOneCDx
2396P
Monday, October 23
Relationship of Tumor Fraction in Circulating Tumor DNA (ctDNA) with Prognosis in Patients with Advanced Urothelial Cancer
Fox Chase Cancer Center, Temple University
FoundationOneLiquid CDx
1946P
Monday, October 23
Primary Sarcomas of the Urinary Bladder (BSar): A Genomic Landscape and Clinical Outcome Study
Upstate Medical University, University of Washington, Moffit Cancer Center, MD Anderson Cancer Center, San Rafael University
FoundationOneCDx
2395P
Monday, October 23
Micropapillary Histology (MPUC) and Extra-cellular Domain ERBB2 (ERBB2 ECD+) Mutations in Urothelial Bladder Cancer (UBC)
Upstate Medical University, University of Washington, Moffit Cancer Center, MD Anderson Cancer Center, San Rafael University
FoundationOneCDx
2400P
Monday, October 23
Frequency and Nature of Genomic Alterations (GA) in ERBB2-altered Urothelial Bladder Cancer (UBC)
Upstate Medical University, University of Washington, Moffit Cancer Center, MD Anderson Cancer Center, San Rafael University